SR One is a transatlantic biotechnology venture capital firm that partners with founders and entrepreneurs to translate innovative science into transformative medicines. Originally founded in 1985 as the corporate venture capital arm of GlaxoSmithKline, SR One completed its spin-out from GSK in 2020 and now operates as an independent firm with offices in Redwood City, California, and London. Its most recent fund (Fund II) closed at $600 million in March 2023.
56% of their portfolio is in Biotech & Life Sciences. Deal activity increased 36% year-over-year (15 deals in the last 12 months). Average disclosed round size is $85.1M (across 136 rounds with reported amounts).
Portfolio
95
Fund Size
$600M
Top Stage
Series B
Last 12 Mo
15
Team
Lyla Youssef, PhD
Associate
Amit Mehta, PhD
US Investments
Briana Wilson
Senior Administrative Assistant
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Crystalys | Series A | $205M | Sep 2026 |
| CCorxel | Series D | $287M | Sep 2026 |
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Draig Therapeutics | Series B | $65M | Jul 2026 |
 Fore Biotherapeutics | Unknown | $67.4M | Jul 2026 |
 Windward Bio | Unknown | $165M | May 2026 |
 Windward | Unknown | $165M | May 2026 |
 Immutrin | Series A | $87M | Mar 2026 |
| CCorxel | Series D | $287M | Jan 2026 |
| CCorxel Pharmaceuticals Limited | Series D | $287M | Jan 2026 |
 Poplar | Series A | $2.1M | Jan 2026 |
| AAirNexis | Series A | $200M | Jan 2026 |
 Addition Therapeutics | Unknown | $100M | Dec 2025 |
 VeraDermics | Series C | — | Oct 2025 |
 Mission Therapeutics | Unknown | $13.3M | Oct 2025 |
| Crystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
 Avenzotx | Series B | $60M | Sep 2025 |
 Charm Therapeutics | Series B | — | Sep 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
| Draig Therapeutics | Series A | $140M | Jun 2025 |
| Fore Biotherapeutics | Series D | $38M | May 2025 |
| FFore Bio | Series D | $38M | May 2025 |
| Windward Bio | Series A | $200M | Jan 2025 |
| Draig Therapeutics | Series A | $140M | Jan 2025 |
 Avenzo Therapeutics | Series B | $60M | Jan 2025 |
Top Co-Investors
Last updated: 20 October 2026